trending Market Intelligence /marketintelligence/en/news-insights/trending/2-zZHwfXCfE9m4tRObaNmg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Ipsen CEO departs to lead newly formed Swiss gene-therapy maker

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Ipsen CEO departs to lead newly formed Swiss gene-therapy maker

Ipsen SA said David Meek resigned as CEO and as a board member, effective Dec. 31, to join Switzerland-based FerGene as president and CEO.

Meek has been the CEO of the French biopharmaceutical company since July 2016.

Privately held FerGene, a unit of Ferring Holding SA, is a new joint venture between Ferring Pharmaceuticals Inc. and private equity firm Blackstone Life Sciences Advisors LLC that aims to develop Ferring's experimental gene therapy nadofaragene firadenovec for bladder cancer.

Ipsen said CFO Aymeric Le Chatelier will act as interim CEO as of Jan. 1, 2020. Ipsen's board has asked the nominations committee to immediately begin the search for a new CEO.